Search Results - "Limon, Maria Luisa"

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study by Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B, Dragovich, Tomislav, Shah, Usman, Abdullaev, Sandzhar, Gricar, Joseph, Ledeine, Jean-Marie, Overman, Michael James, Lonardi, Sara

“…Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite…”
Get full text

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) by Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert

“…Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in…”
Get full text

A Cross-Sectional Validation Study of Camry EH101 versus JAMAR Plus Handheld Dynamometers in Colorectal Cancer Patients and Their Correlations with Bioelectrical Impedance and Nutritional Status by Jiménez-Sánchez, Andrés, Pereira-Cunill, José Luis, Limón-Mirón, María Luisa, López-Ladrón, Amelia, Salvador-Bofill, Francisco Javier, García-Luna, Pedro Pablo

“…Reduced muscle strength (dynapenia) and mass (atrophy) are prognostic factors in oncology. Measuring maximal handgrip strength with dynamometers is feasible…”
Get full text

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C by Almhanna, Khaldoun, Miron, Maria Luisa Limon, Wright, David, Gracian, Antonio Cubillo, Hubner, Richard A., Van Laethem, Jean-Luc, López, Carolina Muriel, Alsina, Maria, Muñoz, Frederico Longo, Bendell, Johanna, Firdaus, Irfan, Messersmith, Wells, Ye, Zhan, Fasanmade, Adedigbo A., Danaee, Hadi, Kalebic, Thea

“…Summary Background The first-in-class antibody–drug conjugate TAK-264 (formerly MLN0264) consists of an antibody targeting guanylyl cyclase C (GCC) conjugated…”
Get full text

Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer by Estevez-Garcia, Purificacion, Rivera, Fernando, Molina-Pinelo, Sonia, Benavent, Marta, Gómez, Javier, Limón, Maria Luisa, Pastor, Maria Dolores, Martinez-Perez, Julia, Paz-Ares, Luis, Carnero, Amancio, Garcia-Carbonero, Rocio

“…Fluoropyrimidine-based chemotherapy (CT) has been the mainstay of care of metastatic colorectal cancer (mCRC) for years. Response rates are only observed,…”
Get full text

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer by Jiménez-Fonseca, Paula, Carmona-Bayonas, Alberto, Sánchez Lorenzo, Maria Luisa, Plazas, Javier Gallego, Custodio, Ana, Hernández, Raquel, Garrido, Marcelo, García, Teresa, Echavarría, Isabel, Cano, Juana María, Rodríguez Palomo, Alberto, Mangas, Monserrat, Macías Declara, Ismael, Ramchandani, Avinash, Visa, Laura, Viudez, Antonio, Buxó, Elvira, Díaz-Serrano, Asunción, López, Carlos, Azkarate, Aitor, Longo, Federico, Castañón, Eduardo, Sánchez Bayona, Rodrigo, Pimentel, Paola, Limón, Maria Luisa, Cerdá, Paula, Álvarez Llosa, Renata, Serrano, Raquel, Lobera, Maria Pilar Felices, Alsina, María, Hurtado Nuño, Alicia, Gómez-Martin, Carlos

“…Background Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced…”
Get full text

Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study by Overman, Michael J, Gelsomino, Fabio, Aglietta, Massimo, Wong, Mark, Limon Miron, Maria Luisa, Leonard, Gregory, García-Alfonso, Pilar, Hill, Andrew G, Cubillo Gracian, Antonio, Van Cutsem, Eric, El-Rayes, Bassel, McCraith, Stephen M, He, Beilei, Lei, Ming, Lonardi, Sara

“…BackgroundProgrammed death-1 (PD-1) inhibitors, including nivolumab, have demonstrated long-term survival benefit in previously treated patients with…”
Get full text

Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study by Valladares-Ayerbes, Manuel, Garcia-Alfonso, Pilar, Muñoz Luengo, Jorge, Pimentel Caceres, Paola Patricia, Castillo Trujillo, Oscar Alfredo, Vidal-Tocino, Rosario, Llanos, Marta, Llorente Ayala, Beatriz, Limon Miron, Maria Luisa, Salud, Antonieta, Cirera Nogueras, Luis, Garcia-Carbonero, Rocio, Safont, Maria Jose, Falco Ferrer, Esther, Aparicio, Jorge, Vicente Conesa, Maria Angeles, Guillén-Ponce, Carmen, Garcia-Teijido, Paula, Medina Magan, Maria Begoña, Busquier, Isabel, Salgado, Mercedes, Lloansí Vila, Ariadna

“…The serial analysis of cell-free DNA (cfDNA) enables minimally invasive monitoring of tumor evolution, providing continuous genetic information. PERSEIDA was…”
Get full text

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry by Jiménez Fonseca, Paula, Carmona-Bayonas, Alberto, Hernández, Raquel, Custodio, Ana, Cano, Juana Maria, Lacalle, Alejandra, Echavarria, Isabel, Macias, Ismael, Mangas, Monserrat, Visa, Laura, Buxo, Elvira, Álvarez Manceñido, Felipe, Viudez, Antonio, Pericay, Carles, Azkarate, Aitor, Ramchandani, Avinash, López, Carlos, Martinez de Castro, Eva, Fernández Montes, Ana, Longo, Federico, Sánchez Bayona, Rodrigo, Limón, Maria Luisa, Diaz-Serrano, Asun, Martin Carnicero, Alfonso, Arias, David, Cerdà, Paula, Rivera, Fernando, Vieitez, Jose Maria, Sánchez Cánovas, Manuel, Garrido, M, Gallego, J

“…Background: The choice of chemotherapy in HER2-negative gastric cancer is based on centre’s preferences and adverse effects profile. No schedule is currently…”
Get full text

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry by Jiménez Fonseca, Paula, Carmona-Bayonas, Alberto, Hernández, Raquel, Custodio, Ana, Cano, Juana Maria, Lacalle, Alejandra, Echavarria, Isabel, Macias, Ismael, Mangas, Monserrat, Visa, Laura, Buxo, Elvira, Álvarez Manceñido, Felipe, Viudez, Antonio, Pericay, Carles, Azkarate, Aitor, Ramchandani, Avinash, López, Carlos, Martinez de Castro, Eva, Fernández Montes, Ana, Longo, Federico, Sánchez Bayona, Rodrigo, Limón, Maria Luisa, Diaz-Serrano, Asun, Martin Carnicero, Alfonso, Arias, David, Cerdà, Paula, Rivera, Fernando, Vieitez, Jose Maria, Sánchez Cánovas, Manuel, Garrido, M, Gallego, J

Get full text

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study by Andre, Thierry, Elez, Elena, Van Cutsem, Eric, Jensen, Lars Henrik, Bennouna, Jaafar, Mendez, Guillermo, Schenker, Michael, De La Fouchardiere, Christelle, Limon, Maria Luisa, Yoshino, Takayuki, Li, Jin, Lenz, Heinz-Josef, Manzano Mozo, Jose Luis, Tortora, Giampaolo, Garcia-Carbonero, Rocio, Cela, Elvis, Yang, Yingsi, Lei, Ming, Jin, Lixian, Lonardi, Sara

“…LBA768 Background: Patients (pts) with MSI-H/dMMR mCRC have poor outcomes with standard chemo ± targeted therapies. NIVO ± IPI are approved in previously…”
Get full text

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142 by Lenz, Heinz-Josef, Overman, Michael J., Van Cutsem, Eric, Limon, Maria Luisa, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, Garcia-Alfonso, Pilar, Neyns, Bart, Gelsomino, Fabio, Cardin, Dana Backlund, Dragovich, Tomislav, Shah, Usman, McCraith, Stephen, Wang, Rui, Lei, Ming, Yao, Jin, Jin, Lixian, Lonardi, Sara

“…97 Background: NIVO + IPI demonstrated robust, durable clinical benefit and was well tolerated as a 1L therapy in pts with MSI-H/dMMR mCRC in the phase 2…”
Get full text

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer by Fogelman, David, Cubillo, Antonio, García‐Alfonso, Pilar, Mirón, María Luisa Limón, Nemunaitis, John, Flora, Daniel, Borg, Christophe, Mineur, Laurent, Vieitez, Jose M., Cohn, Allen, Saylors, Gene, Assad, Albert, Switzky, Julie, Zhou, Li, Bendell, Johanna

“…Background The Janus kinase/signal transducer and activator of transcription (JAK‐STAT) signaling pathway plays a key role in the systemic inflammatory…”
Get full text

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer by Molina-Pinelo, Sonia, Carnero, Amancio, Rivera, Fernando, Estevez-Garcia, Purificacion, Bozada, Juan Manuel, Limon, Maria Luisa, Benavent, Marta, Gomez, Javier, Pastor, Maria Dolores, Chaves, Manuel, Suarez, Rocio, Paz-Ares, Luis, de la Portilla, Fernando, Carranza-Carranza, Andres, Sevilla, Isabel, Vicioso, Luis, Garcia-Carbonero, Rocio

“…MicroRNAs (miRNAs) are involved in numerous biological and pathological processes including colorectal cancer (CRC). The aim of our study was to evaluate the…”
Get full text

Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer by Cascinu, Stefano, Bodoky, György, Muro, Kei, Van Cutsem, Eric, Oh, Sang Cheul, Folprecht, Gunnar, Ananda, Sumitra, Girotto, Gustavo, Wainberg, Zev A., Miron, Maria Luisa Limon, Ajani, Jaffer, Wei, Ran, Liepa, Astra M., Carlesi, Roberto, Emig, Michael, Ohtsu, Atsushi

“…Background In the intent‐to‐treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms,…”
Get full text

Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial by Rivera, Fernando, Izquierdo-Manuel, Marta, García-Alfonso, Pilar, Martínez de Castro, Eva, Gallego, Javier, Limón, María Luisa, Alsina, María, López, Luis, Galán, Maica, Falcó, Esther, Manzano, José Luis, González, Encarna, Muñoz-Unceta, Nerea, López, Carlos, Aranda, Enrique, Fernández, Eva, Jorge, Mónica, Jiménez-Fonseca, Paula

“…Perioperative chemotherapy improves overall survival (OS) and disease-free survival (DFS) compared with surgery alone in patients with resectable gastric…”
Get full text

Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer by Carmona-Bayonas, Alberto, Jimenez-Fonseca, Paula, Garrido, Marcelo, Custodio, Ana, Hernandez, Raquel, Lacalle, Alejandra, Cano, Juana María, Aguado, Gema, Martínez de Castro, Eva, Alvarez Manceñido, Felipe, Macias, Ismael, Visa, Laura, Martín Richard, Marta, Mangas, Monserrat, Sánchez Cánovas, Manuel, Longo, Federico, Iglesias Rey, Leticia, Martínez Lago, Nieves, Martín Carnicero, Alfonso, Sánchez, Ana, Azkárate, Aitor, Limón, María Luisa, Hernández Pérez, Carolina, Ramchandani, Avinash, Pimentel, Paola, Cerdá, Paula, Serrano, Raquel, Gil-Negrete, Aitziber, Marín, Miguel, Hurtado, Alicia, Sánchez Bayona, Rodrigo, Gallego, Javier

“…Research into cancer-associated thrombosis (CAT) entails managing dynamic data that pose an analytical challenge. Thus, methods that assume proportional…”
Get more information

Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry by Carmona-Bayonas, Alberto, Jiménez-Fonseca, Paula, Echavarria, Isabel, Sánchez Cánovas, Manuel, Aguado, Gema, Gallego, Javier, Custodio, Ana, Hernández, Raquel, Viudez, Antonio, Cano, Juana María, Martínez de Castro, Eva, Macías, Ismael, Martín Carnicero, Alfonso, Garrido, Marcelo, Mangas, Monserrat, Álvarez Manceñido, Felipe, Visa, Laura, Azkarate, Aitor, Ramchandani, Avinash, Fernández Montes, Ana, Longo, Federico, Sánchez, Ana, Pimentel, Paola, Limón, María Luisa, Arias, David, Cacho Lavin, Diego, Sánchez Bayona, Rodrigo, Cerdá, Paula, García Alfonso, Pilar

“…The effect of surgery for metastases in patients with esophagogastric cancer is unknown, given the lack of randomized clinical trials; likewise, the criteria…”
Get full text

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry by Cotes Sanchís, Almudena, Gallego, Javier, Hernandez, Raquel, Arrazubi, Virginia, Custodio, Ana, Cano, Juana María, Aguado, Gema, Macias, Ismael, Lopez, Carlos, López, Flora, Visa, Laura, Garrido, Marcelo, Martínez Lago, Nieves, Fernández Montes, Ana, Limón, María Luisa, Azkárate, Aitor, Pimentel, Paola, Reguera, Pablo, Ramchandani, Avinash, Cacho, Juan Diego, Martín Carnicero, Alfonso, Granja, Mónica, Martín Richard, Marta, Hernández Pérez, Carolina, Hurtado, Alicia, Serra, Olbia, Buxo, Elvira, Vidal Tocino, Rosario, Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Buyukhatipoglu, Hakan

“…Background Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and…”
Get full text

Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry by Valcarcel, Sena, Gallego, Javier, Jimenez-Fonseca, Paula, Diez, Marc, de Castro, Eva Martínez, Hernandez, Raquel, Arrazubi, Virginia, Custodio, Ana, Cano, Juana María, Montes, Ana Fernández, Macias, Ismael, Visa, Laura, Calvo, Aitana, Tocino, Rosario Vidal, Lago, Nieves Martínez, Limón, María Luisa, Granja, Mónica, Gil, Mireia, Pimentel, Paola, Macia-Rivas, Lola, Pérez, Carolina Hernández, Mangas, Montserrat, Carnicero, Alfonso Martín, Cerdà, Paula, Gonzalez, Lucía Gomez, Navalon, Francisco Garcia, Rambla, Mª Dolores Mediano, Richard, Marta Martin, Carmona-Bayonas, Alberto

“…Purpose This study aimed to compare ramucirumab-paclitaxel versus chemotherapy in second-line (2L) advanced gastroesophageal cancer (aGEC) based on HER2 status…”
Get full text